Tenofovir Disoproxil Fumarate

Clinical Infectious Diseases

Volumn 37, Issue 7, 2003, Pages 944-950

  Gallant, Joel E ^a   Deresinski, Stanley ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; CHOLESTEROL; CIDOFOVIR; DIDANOSINE; GANCICLOVIR; PROBENECID; RITONAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; TRIACYLGLYCEROL; VALACICLOVIR; ZALCITABINE; ZIDOVUDINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS RESISTANCE; DISEASE PREDISPOSITION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG TOLERABILITY; FLATULENCE; FOLLOW UP; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAXIMUM ALLOWABLE CONCENTRATION; OSTEOLYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS MUTATION; VIRUS REPLICATION; VIRUS STRAIN;

ADENINE; ANTI-HIV AGENTS; DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; HEPATITIS B VIRUS; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTATION; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS;

EID: 0142075844     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/378068     Document Type: Review

References (32)

1. Squires K, Pozniak AL, Pierone G, et al. Tenofovir DF in antiretroviral-experienced, nucleoside-resistant HIV-1 infected patients with incomplete viral suppression. Ann Intern Med 2003; 139:313-20.
2. Margot NA, Johnson A, Cheng A, Coakley, DF, Miller MD. Final 48 week genotypic and phenotypic analyses of study 907: tenofovir DF added to stable background regimens [abstract 414-W]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002:209.
3. Margot NA, Zhong L, Wulfsohn M, Cheng AK, Miller MD. Probability and durability of achieving <50 copies/mL of HIV RNA by treatment intensification with tenofovir DF (TDF) [abstract H1077]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002:267.
4. Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002; 16:1257-63.
5. Barditch-Crovo P, Decks SG, Collier A, et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2001; 45:2733-9.
6. Louie M, Hogan C, Hurley A, et al. Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naïve chronically HIV-1-infected individuals. AIDS 2003; 17:1151-6.
7. Staszewski S, Gallant JE, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine when used in combination with lamivudine and efavirenz in antiretroviral naïve patients: 96-week preliminary interim results [abstract 564b]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2003:259.
8. White KL, Margot NA, Wrin T, Petropoulos CH, Miller MD, Naeger LK. Molecular mechanisms of resistance to human immunodeficiency virus type I with reverse transcriptase mutations K65R and K65R + M184V and their effects on enzyme function and viral replication capacity. Antimicrob Agents Chemother 2002; 46:3437-46.
9. McColl DJ, Margot NA, Cheng AK, Miller MD. Development of K65R versus thymidine analog-association mutations (TAMs) in antiretroviral-treated patients [abstract P206]. In: Program and abstracts of the 6th International Congress on Drug Therapy in HIV Infection (Glasgow, Scotland). 2002.
10. Miller MD, Margot NA, McColl DJ, Coakley DF, Cheng AK. Characterization of virologic failure through 96 weeks among treatment-naïve patients taking tenofovir DF (TDF) or stavudine (d4T) in combination with lamivudine (3TC) and efavirenz (EFV) [abstract 553]. In: Program and abstracts of the the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment (Paris). Antiviral Ther 2003; 8(Suppl 1):S333.
11. Miller MD, Margot NA, Lu B. Effect of baseline nucleoside-associated resistance on response to tenofovir DF (TDF) therapy: integrated analyses of studies 902 and 907 [abstract 43]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002.
12. Naeger LK, Margot NA, Miller MD. ATG-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 2002; 46:2179-84.
13. Lu B, Hellman NS, Bates M, Dawson K, Rooney J, Miller MD. Determination of clinical cut-offs for reduced response to tenofovir DF therapy in antiretroviral-experienced patients [abstract 125]. In: Program and abstracts of the XI International HIV Drug Resistance Workshop (Seville, Spain) Antivir Ther 2002; 7:S137.
14. Birkus G, Hitchcock MJM, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside analog transcriptase inhibitors. Antimicrob Agents Chemother 2002; 46:716-23.
15. Birkus G, Hajek M, Kramata P, et al. Tenofovir diphosphate is a poor substrate and a weak inhibitor of rat DNA polymerases α, δ, and ε. Antimicrob Agents Chemother 2002; 46:1610-3.
16. Gallant JE, Staszewski S, Pozniak AL, et al. Favorable lipid and mitochondrial (mt) DNA profile for tenofovir disoproxil fumarate (TDF) compared to stavudine (d4T) in combination with lamivudine (3TC) and efavirenz (EFV) in antiretroviral therapy (ART) naïve patients: a 48 week interim analysis [abstract 3983]. In: Program and abstracts of the 42nd Interscience Congress on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002.
17. Reynes J, Peyriere H, Merle De Boever C, Le Moing V. Renal tubular injury and severe hypophosphoremia (Fanconi syndrome) associated with tenofovir therapy [abstract 717]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2003:314.
18. Blick G, Grieger-Zanlungo, Garton T, Hatten E, Lopez RJ. Tenofovir may cause severe hypophosphatemia in HIV/AIDS patients with prior adefovir-induced renal tubular acidosis [abstract 718]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2003:314.
19. Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003; 36:1070-3.
20. Tenofovir disoproxil fumarate. In: Proceedings of the FDA Antiviral Drug Products Advisory Committee Meeting. Silver Spring, MD: US Food and Drug Administration, 2001.
21. Kearney BP, Isaacson E, Sayre J, Plummer A, Cheng A. Didanosine and tenofovir DF drug-drug interaction: assessment of didanosine dose reduction [abstract 533]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2003:245.
22. Taburet AM, Piketty C, Gérard L, et al. Pharmacokinetic parameters of atazanavir/ritonavir when combined to tenofovir in HIV infected patients with multiple treatment failures: a sub-study of Puzzle-2-ANRS 107 trial [abstract 537]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2003:247.
23. Benhamou Y, Tubiana R, Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamviudine-resistant hepatitis B virus [letter]. N Engl J Med 2003; 348:177-8.
24. Nunez M, Perez-Olmeda M, Diaz B, Rios P, Gonzalez-Lahoz J, Soriano V. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responsive to lamivudine. AIDS 2002; 16:2352-4.
25. Ristig MB, Crippin J, Aberg JA, et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-α and lamivudine therapy have failed. J Infect Dis 2002; 186:1844-7.
26. Nelson M, Portsmouth S, Stebbing J, et al. An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals. AIDS 2003; 17:F7-10.
27. Cooper D, Dore G, Pozniak A, et al. Tenofovir DF and lamivudine combination therapy compared to lamviduine alone for HBV in therapy-naive HIV/HBV co-infected patients: 48 week interim results [abstract 825]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2003:358.
28. Panel on Clinical Practices for Treatment of HIV Infection, Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 14 July 2003. Available at: http://www.hivatis.org.
29. Farthing C, Khanlou H, Yeh V. Early virologic failure in a pilot study evaluating the efficacy of abacavir, lamivudine, and tenofovir in the treatment naïve HIV-infected patients [abstract 43]. In: Program and abstracts of the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment (Paris). Antiviral Ther 2003; 8(Suppl 1):S195.
30. Gallant JE, Rodriguez AE, Weinberg W, et al. Early non-response to tenofovir DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV) + ABC and 3TC: ESS30009 unplanned interim analysis [abstract 4496]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2003.
31. Tsai C-C, Follis KE, Sabo A, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl) adenine. Science 1995; 270:1197-9.
32. Viread [package insert]. Foster City, CA: Gilead Sciences, 2003.